Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WockhardtNSE:WOCKPHARMA +1.30%59 Interest Coverage is 2.86 as of Mar. 2026, which is 303% above its 10-year median of 0.71. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 59/100 and a GF Value™ of ₹1,268.66 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 687 Drug Manufacturers companies, Wockhardt ranks worse than 86.32% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Wockhardt's
Operating Income
for the
three
months ended in Mar. 2026 was ₹1,430 Mil. Wockhardt's Interest Expense for the
three
months ended in Mar. 2026 was ₹-500 Mil.
Wockhardt's interest coverage for the quarter that ended in Mar. 2026 was 2.86.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Wockhardt's Interest Coverage or its related term are showing as below:
NSE:WOCKPHARMA'
s Interest Coverage Range Over the Past 10 Years
Min: 0.18 Med: 0.71 Max: 1.89
Current: 1.89
NSE:WOCKPHARMA's Interest Coverage is ranked worse than 86.32% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs NSE:WOCKPHARMA: 1.89
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Wockhardt Interest Coverage Related Terms
Wockhardt Interest Coverage Historical Data
* Premium members only.
The historical data trend for Wockhardt's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:WOCKPHARMA vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Wockhardt's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (NSE:WOCKPHARMA) has a Interest Coverage of 2.86 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Wockhardt and its competitors. This is 303% above median its historical median of 0.71. Over the past decade, Wockhardt's Interest Coverage has ranged from 0.18 to 1.89. According to the industry distribution chart, Wockhardt ranks #593 out of 687 companies in the Drug Manufacturers industry, placing it in the top 86.3%.
Is Wockhardt's Interest Coverage too high?
Wockhardt's current Interest Coverage of 2.86 is 303% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.89. The Drug Manufacturers industry median Interest Coverage is 12.75. Wockhardt's value of 2.86 is 77.6% below this industry median. Based on the distribution chart, Wockhardt ranks #593 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wockhardt has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #593 out of 687 companies for Interest Coverage. This places Wockhardt in the lower half of its industry. The industry median Interest Coverage is 12.75. Wockhardt's value of 2.86 is 77.6% below this benchmark. Historically, Wockhardt's own Interest Coverage has ranged from 0.18 to 1.89 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 12.75, Wockhardt has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wockhardt's current Interest Coverage of 2.86 is 77.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Interest Coverage is 2.86, which is 303% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,268.66, compared to a current price of ₹1,900.70 — trading 49.8% above its estimated fair value. The current Interest Coverage is 2.86, which is 303% above median its 10-year median of 0.71 and 77.6% below the Drug Manufacturers industry median of 12.75. Wockhardt's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Interest Coverage is 2.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,900.70 is trading 49.8% above its estimated GF Value™ of ₹1,268.66.
GuruFocus considers Wockhardt to be Significantly Overvalued.
Key valuation signals for NSE:WOCKPHARMA:
Interest Coverage: 2.86 (303% above median its 10-year median of 0.71)
GF Value™: ₹1,268.66 vs. price of ₹1,900.70 (49.8% above fair value)
Industry Position: 77.6% below the Drug Manufacturers median (#593 of 687)
No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
59GF Score
Get the complete analysis for NSE:WOCKPHARMA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WOCKPHARMA has been successfully added to your 
